Skip to main content
. 2016 Mar 21;22(11):3165–3174. doi: 10.3748/wjg.v22.i11.3165

Table 2.

Epidemiological and clinical profiles of patients

Age1 Gender Precedence Mode of Duration of HBV Genotype2 Previous Time without Treatment3 (mo) Follow-up (mo) Sampling
transmission infection (yr) treatment
Pat #1 43 Male Western Europe Horizontal 20 Undetermined IFN 84 74 8
Pat #2 30 Male Equatorial Ginnea Unknown Unknown A No 5 4
Pat #3 41 Male Equatorial Ginnea Unknown Unknown E No 2 3
Pat #4 43 Male Eastern Europe Unknown Unknown A No 5 3
Pat #5 45 Male Western Europe IVD Unknown A No 4 4
Pat #6 38 Female Western Europe Horizontal 20 D IFN 36 94 10
Pat #7 35 Female Western Europe Horizontal 25 E IFN 60 89 13
Pat #8 55 Female Western Europe Unknown Unknown D No 17 3
Pat #9 37 Male Equatorial Ginnea IVD 22 A IFN/ADV 8 77 12
Pat #10 31 Female Western Europe Horizontal 20 D IFN 12 78 12
Pat #11 46 Male Western Europe IVD 25 A No 53 4
Pat #12 42 Male Western Europe Unknown 26 D No 93 13
Pat #13 45 Male Western Europe Unknown Unknown A No 42 3
Pat #14 39 Male Western Europe IVD 20 D No 41 6
Pat #15 53 Male Western Europe IVD 25 D No 89 14
Pat #16 38 Female Equatorial Ginnea Unknown Unknown E No 9 5
1

Data of age are referred to the first sample analyzed of each patient;

2

HBV genotype data correspond to the LiPA/PCR-sequencing assays;

3

Time interval between the end of the previous treatment and the sampling of the first sera included in this study. No statistical differences in the route of infection, duration of infection, or previous antiviral treatment were found between patients infected with the different HBV genotypes. HBV: Hepatitis B virus; IFN: Interferon; ADV: Adefovir; IVD: Intra venous drug user.